Natixis Advisors
ROIV icon

Natixis Advisors’s Roivant Sciences ROIV Stock Holding History

Natixis Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.74M Buy
105,637
+9,861
+10% +$291K ﹤0.01% 1010
2026
Q1 		$2.65M Buy
95,776
+32,195
+51% +$827K ﹤0.01% 1015
2025
Q4 		$1.38M Buy
63,581
+2,542
+4% +$50.2K ﹤0.01% 1165
2025
Q3 		$924K Sell
61,039
-8,496
-12% -$105K ﹤0.01% 1347
2025
Q2 		$784K Buy
69,535
+33,102
+91% +$359K ﹤0.01% 1370
2025
Q1 		$368K Sell
36,433
-15,187
-29% -$164K ﹤0.01% 1515
2024
Q4 		$611K Sell
51,620
-102,097
-66% -$1.21M ﹤0.01% 1426
2024
Q3 		$1.77M Buy
153,717
+11,726
+8% +$134K ﹤0.01% 1123
2024
Q2 		$1.5M Buy
141,991
+15,280
+12% +$167K ﹤0.01% 1138
2024
Q1 		$1.34M Buy
126,711
+64,352
+103% +$694K ﹤0.01% 1136
2023
Q4 		$699K Buy
+62,359
New +$608K ﹤0.01% 1318

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Natixis Advisors's ROIV Position: Q2 2026 in Review

Natixis Advisors increased its Roivant Sciences (ROIV) stake by 10% in Q2 2026, buying an estimated $291K and bringing the position to 105,637 shares worth $3.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1010.

Natixis Advisors first reported a position in ROIV in Q4 2023 and has held it in 11 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Natixis Advisors held 105,637 shares of Roivant Sciences worth $3.74M as of Q2 2026.
  • Natixis Advisors bought 9,861 Roivant Sciences shares in Q2 2026, an estimated $291K.
  • Roivant Sciences made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1010 holding.
  • Natixis Advisors first reported a position in Roivant Sciences in Q4 2023 and has held it in 11 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.